Guggenheim Reduces PT on Eli Lilly and Company (LLY) to $1,161, Reiterates 'Buy' Rating

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy and hold for 20 years.

On January 20, 2026, Guggenheim reduced its price target on Eli Lilly and Company (NYSE:LLY) from $1,163 to $1,161, while reiterating a ‘Buy’ rating. The update came as the firm made a routine model update ahead of the company’s upcoming Q4 results.

On the same day, Eli Lilly and Company (NYSE:LLY) announced that the FDA granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with disease progression following prior therapies. Following encouraging Phase 1a/b data, the designation speeds up development timelines and regulatory engagement, improving the company’s oncology pipeline visibility substantially.

In presentations at ASCO 2025 and ESMO 2025, responses were shown across all dose levels and folate receptor alpha expression, including in patients progressing on prior mirvetuximab. Moreover, the results showed a favorable tolerability profile, alongside limited serious safety signals. Now, Eli Lilly and Company (NYSE:LLY) stands on a strong footing, with the asset now advancing into the global Phase 3 Framework-01 trial that positions sofetabart mipitecan as a potential differentiated entrant in a high unmet-need ovarian cancer market.

Eli Lilly and Company (NYSE:LLY), a global pharmaceutical company, focuses on developing medicines across diabetes, oncology, immunology, and neuroscience.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: What Are the Best Stocks to Buy Right Now? and 10 Stocks Under $1 That Will Explode.

Disclosure: None.